- Clinical Development
- Therapeutic Expertise
- News & Resources
Heart disease is the number one cause of death globally, representing more than 30% of all deaths, according to the World Health Organization. While death rates from heart disease and stroke are falling due in large part to new drug treatments, the war against heart disease and stroke is far from won. In America alone, according to the American Heart Association, every 39 seconds an American dies from cardiovascular disease, and more than 82 million Americans have at least one type of the disease. Low- and middle-income countries are disproportionately affected: over 80% of cardiovascular deaths take place in lower-to middle income countries, occurring almost equally in men and women. Many people who survive heart attacks develop heart failure, a chronic disease that affects millions worldwide. Opportunities for new therapies exist.
At SynteractHCR, our longstanding dedication to this area of research stems from our roots in a cardiovascular-focused drug development company, where we conducted studies in over 7,000 patients with multiple products. Since that time, we have built on that base by conducting drug, diagnostic and device trials for a total of 155 projects and 22,200 subjects on many approved products. SynteractHCR has access to suitable patients and experienced investigative sites. We have the clinical development and therapeutic expertise to efficiently manage studies for new drugs and devices that promise to continue the remarkable progress against heart disease and stroke and to raise the quality of life for patients suffering from cardiovascular diseases.